ClinicalTrials.gg
RecruitingNCT05519241Updated Nov 18, 2026

A Phase I Intravesical PPM Therapy for NMIBC

A Phase 1 interventional study of PLZ4-coated paclitaxel-loaded micelles (PPM) in Non-muscle-invasive Bladder Cancer, sponsored by VA Office of Research and Development. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by VA Office of Research and Development · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States — 39 open to participants now, 60 under way, 15 of them phase 3. Non-Muscle Invasive Bladder Neoplasms · United States.

Planned enrollment
65th of 93
29 · median 55
Started
2022
with 8 others
Phase 1
20 of 114
5 open now
Primary completion
2027-08
later than 19 of 59 live
Registered
64th of 114
by date

Among the 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States, this one is the 65th largest by planned enrollment of the 93 interventional ones that give a count, is one of 9 that started in 2022, is one of 20 in phase 1, reaches primary completion later than 19 of the 59 other live ones, and was the 64th registered.

Non-Muscle Invasive Bladder Neoplasms

295 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 127 are open to participants now.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Open to participants now

39 of the 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 78 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This clinical trial is to determine the safety and effectiveness of an investigational bladder cancer drug named "PLZ4-coated paclitaxel-loaded nanoscale micelle (PPM)." PPM is tiny particles that contain the chemotherapy drug paclitaxel. PLZ4 is a molecule that can possibly guide PPM to specifically target and deliver paclitaxel into and kill bladder cancer cells. In this trial, PPM will be instilled into the bladder cavity to treat bladder cancer that does not invade into the muscle layer of the bladder and that has failed the treatment of another drug Bacillus Calmette-Guérin (BCG). Up to 29 patients will be enrolled into the trial. The main goal of this trial is to determine the dose of PPM for future clinical trials, assess the toxicity and obtain preliminary data regarding its effectiveness.

Read the detailed description

The goal of this project is to conduct a Phase I clinical trial to determine the recommended Phase II dose (RP2D) of bladder cancer-targeting micelles loaded with a chemotherapeutic drug paclitaxel (PTX). The investigators previously developed a bladder cancer-specific targeting ligand named PLZ4, and a PLZ4-coated PTX-loaded nanoscale micelle (PPM) platform that can specifically deliver the drug load into bladder cancer cells both in vitro and in vivo. This proposed clinical trial is to conduct a first-in-human trial to use PPM for the treatment of non-myoinvasive bladder cancer (NMIBC). This primary objective of the proposed Phase I trial is to determine the recommended Phase II dose (RP2D) of PPM. The secondary objectives are to assess the toxicity, obtain preliminary efficacy information of PPM, and determine systemic absorption after intravesical instillation of PPM. Up to 29 patients with recurrent or refractory NMIBC after a standard first-line intravesical BCG treatment will be recruited. PPM will be given as intravesical instillation once weekly for six weeks. The toxicity will be assessed by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The efficacy will be determined by urine cytology and cystoscopy after finishing treatment. Molecular correlative studies will be performed.

03

Conditions studied

  • Non-muscle-invasive Bladder Cancer

Keywords

  • non-muscle-invasive bladder cancer
  • BCG-refractory
  • paclitaxel
  • intravesical instillation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must meet all of the following criteria to be eligible for study entry.

  • confirmed bladder carcinoma in situ (CIS) urothelial or urothelial carcinoma, with or without T1 cancer. Patients are eligible if the was done within 3 months of enrollment and a cystoscopy demonstrates no gross disease invasion into muscularis propria within 4 weeks of enrollment.
  • Patient must have BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) or intolerance of treatment with BCG. Treatment of pembrolizumab is not an inclusion or exclusion criteria as intravesical taxane probably has comparable efficacy as intravenous pembrolizumab. BCG-unresponsive disease is defined as being at least one of the following:

    • Persistent or recurrent CIS alone or with recurrent Ta/T1 (noninvasive papillary disease/tumor invades the subepithelial connective tissue) disease within 12 months of completion of adequate BCG therapy
    • Recurrent high-grade Ta/T1 disease within 6 months of completion of adequate BCG therapy
    • T1 high-grade disease at the first evaluation following an induction BCG course

In this context, adequate BCG therapy is defined as at least one of the following:

  • At least five of six doses of an initial induction course plus at least two of three doses of maintenance therapy
  • At least five of six doses of an initial induction course plus at least two of six doses of a second induction course

    • Refuse or intolerant of a radical cystectomy recommended by the treating urologist as the standard next therapy per urologic guidelines
    • Performance status: performance status of 0, 1, or 2 or performance status of 50 or higher
    • Patient with greater than 24 months
    • No concurrent radiotherapy, chemotherapy, or other immunotherapy
    • No scheduled radiotherapy, chemotherapy, other immunotherapy, or surgery before the scheduled response evaluation
    • Recovery from prior treatment side effects that might interfere with the study treatment, in the judgment of the participating urologist
    • Laboratory tests performed within 14 days of study enrollment:
  • (AGC/ANC)1,500/uL
  • Platelets100,000/uL [Patients may be transfused to meet this requirement]
  • 8 g/dL [Patients may be transfused to meet this requirement]
  • Calculated (GFR) 50 mL/min/1.73m2
  • Total 2.0 X (\< 3 x ULN for patients with Gilbert's syndrome)
  • , ALT, ALP 3.0 X ULN

    • Adequate pulmonary function with no clinical signs of severe pulmonary dysfunction
    • Negative serum pregnancy test if the study participant is a female and of (non-childbearing is defined as greater than one year or surgically sterilized)
    • Female participants of childbearing potential must adhere to using a medically accepted method of , i.e. a tubal ligation, an approved hormonal contraceptive or an intrauterine device, prior to screening and agree to continue its use during the study and up to 3 months after finishing this study or be surgically sterilized (e.g., hysterectomy or tubal ligation). Males must agree to use barrier methods of birth control while on study
    • Provide signed and HIPAA authorization and agree to comply with all protocol-specified procedures and follow-up evaluations

Exclusion criteria

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from study entry.

  • Existence of cancer at the upper urinary tract
  • Concurrent use of other agents
  • Evidence of regional and/or distant
  • (New York Heart Association) Class III or IV heart failure, uncontrollable supraventricular arrhythmias, any history of a ventricular arrhythmia, or other clinical signs of severe cardiac dysfunction
  • Symptomatic congestive heart failure (CHF), severe/unstable angina pectoris, or myocardial infarction within 6 months prior to study entry
  • Patient has an intractable bleeding disorder (e.g., coagulation factors deficiencies, Von Willebrand Disease)
  • Patient taking medications that affect coagulation, such as aspirin (aspirin 81 mg oral once daily is allowed), Coumadin/Warfarin, heparin, low molecular weight heparin, direct thrombin inhibitors, and direct factor Xa inhibitors. Other nonsteroidal anti-inflammatory drugs (NSAIDs) are allowed as long as they are discontinued the day before therapy.
  • History or evidence of uncontrollable central nervous system (CNS) disease
  • Active systemic infection requiring parenteral antibiotic therapy.
  • Women who are pregnant or nursing
  • Psychiatric illness/social situations that would limit compliance with study requirements
  • Other illness that in the opinion of the investigator would exclude the patient from participating in this study
  • Any other diagnosed within 3 years of trial entry with the exception of:

    • Basal or squamous cell skin cancers, or
    • Noninvasive cancer of the cervix, or
    • Any other cancer deemed to be of low-risk for progression or patient morbidity during trial period, such as localized prostate cancer after definitive treatment and prostate-specific antigen (PSA) less than 0.2 ng/ml.
  • Patients unwilling to or unable to comply with the protocol
  • Patients with impaired decision-making capacity
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
29 participants (estimated)

Study arms

  • Experimental
    Phase I dose-escalation and expansion cohort

    There are three doses at the dose escalation stage: Dose level I: paclitaxel (PTX) 25 Milligrams (mg) or 0.5 Milligrams (mg)/milliliter (ml); Dose Level II: PTX 50 mg or 1.0 mg/ml; Dose Level III: PTX 75 mg or 1.5 mg/ml. At the expansion cohort, up to 12 patients will be recruited and treated with PPM at the PTX dose of 50 mg or 1.0 mg/ml to determine the efficacy.

    Drug: PLZ4-coated paclitaxel-loaded micelles (PPM)

Interventions

  • DrugPLZ4-coated paclitaxel-loaded micelles (PPM)

    PPM will be administrated weekly for 6 times through intravesical instillation into the bladder cavity

06

What researchers measure

Primary outcomes

  1. adverse events

    Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be used to determine any adverse events and assess the grade. All toxicity as well as Grade 3 or higher adverse events will be analyzed.

    Time frame: up to 6 weeks after the last dose

Secondary outcomes

  1. complete response rate

    urine cytology, cystoscopy.

    Time frame: 6 weeks after finishing the last dose of PPM

Other outcomes

  1. blood paclitaxel concentration

    Blood will be drawn up to a few hours after the first dose of PPM at the expansion cohort to determine the systemic paclitaxel absorption.

    Time frame: within 6 hours after administration

07

Study locations

1 of 1 sites recruiting
  • VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
    Boston, Massachusetts 02130-4817, United States
    Recruiting
    • Chong-Xian Pan, MD PhD · Contactchong-xian.pan@va.gov · 857-203-6189
    • Chong-Xian Pan, MD PhD · Principal investigator
08

References and documents

Publications

  • Pan CX, Mossanen M, Ellis JL, Ma AH, Yang C, Farrukh H, Jiao Y, Bhardwaj U, Lee JS, Lara PN, Hynes C, Lin TY, Li Y, Lerner L, Preston MA, Kibel A, Dall'Era M, Lam KS. Phase I first-in-human dose-escalation trial of a bladder cancer-specific nanoparticle in non-muscle-invasive bladder cancer. Nanomedicine (Lond). 2026 Jul;21(13):1865-1871. doi: 10.1080/17435889.2026.2693194. Epub 2026 Jul 8. PubMed 42415671 ↗

Individual participant data

Plan to share: No — The published data is readily available after publications. Unpublished data will be available upon request. No individual participant data will be shared.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Aug 2027, 58 months after the start.

Of 24 phase 1 interventional studies under Non-Muscle Invasive Bladder Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 61. This study's planned 58 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2022
First posted
Aug 29, 2022
StartActual
Oct 10, 2022
Primary completionEst.
Aug 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers and contact details
1 update, last Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Minor edits only
    + 2 other changes: identifiers and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05519241
Responsible party
Sponsor
First posted
Aug 29, 2022
Start date
Oct 10, 2022
Primary completion
Aug 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Chong-Xian Pan, MD PhD
Contact
chong-xian.pan@va.gov
(857) 203-6189
Lori Lerner, MD
Contact
lori.lerner@va.gov
(857) 364-6150
Chong-Xian Pan, MD PhD
principal investigator · VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion